News
VYNE
0.6700
-0.06%
-0.0004
Weekly Report: what happened at VYNE last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at VYNE last week (0427-0501)?
Weekly Report · 05/04 09:00
Weekly Report: what happened at VYNE last week (0420-0424)?
Weekly Report · 04/27 09:00
Weekly Report: what happened at VYNE last week (0413-0417)?
Weekly Report · 04/20 09:00
Weekly Report: what happened at VYNE last week (0406-0410)?
Weekly Report · 04/13 09:00
Weekly Report: what happened at VYNE last week (0330-0403)?
Weekly Report · 04/06 09:00
Weekly Report: what happened at VYNE last week (0323-0327)?
Weekly Report · 03/30 09:00
Faron Pharmaceuticals appoints Heikki Jouttijärvi as CTO; late-stage development activities strengthen
Reuters · 03/26 07:20
Weekly Report: what happened at VYNE last week (0316-0320)?
Weekly Report · 03/23 09:00
Weekly Report: what happened at VYNE last week (0309-0313)?
Weekly Report · 03/16 09:00
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance
TipRanks · 03/12 01:04
Nasdaq Grants Vyne Therapeutics Extension to Regain $1 Minimum Bid Price Compliance
Reuters · 03/11 20:58
Weekly Report: what happened at VYNE last week (0302-0306)?
Weekly Report · 03/09 09:00
Weekly Report: what happened at VYNE last week (0223-0227)?
Weekly Report · 03/02 09:00
Weekly Report: what happened at VYNE last week (0216-0220)?
Weekly Report · 02/23 09:00
Weekly Report: what happened at VYNE last week (0209-0213)?
Weekly Report · 02/16 09:00
Weekly Report: what happened at VYNE last week (0202-0206)?
Weekly Report · 02/09 09:00
Weekly Report: what happened at VYNE last week (0126-0130)?
Weekly Report · 02/02 09:00
VYNE Therapeutics Amends Merger Terms with Yarrow Bioscience
TipRanks · 01/30 21:32
Vyne Therapeutics Amends Merger Agreement With Yarrow Bioscience
Reuters · 01/30 21:11
More
Webull provides a variety of real-time VYNE stock news. You can receive the latest news about Vyne Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VYNE
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.